Company Overview

Vivos Inc. (NASDAQ: RDGL), formerly known as RadioGel™, is a U.S.-based medical device company focused on developing minimally invasive radiotherapy technologies for the treatment of solid tumors. The company operates within the oncology and medical isotope sectors, with its primary commercial and development focus centered on injectable brachytherapy treatments using radioactive isotopes. Its lead product candidate, RadioGel™, is designed to deliver localized beta radiation directly into tumors through a hydrogel-based delivery system intended to limit radiation exposure to surrounding healthy tissue.

The company’s core business strategy is based on advancing proprietary isotope delivery technologies for veterinary and human oncology applications. Vivos has historically concentrated on companion animal cancer treatment as a pathway toward broader human therapeutic applications and regulatory advancement. The company evolved from earlier development-stage operations focused on isotope therapeutics and rebranded around the RadioGel platform as it refined its commercialization and regulatory strategy. Public disclosures and investor materials indicate that Vivos positions itself as a niche participant in localized cancer therapy with emphasis on precision treatment, outpatient administration potential, and reduced invasiveness compared with conventional surgery or external beam radiation.

Business Operations

Vivos generates its operational activity primarily through research, development, regulatory advancement, and pre-commercialization efforts related to the RadioGel system. The company’s principal operating activities include isotope sourcing, hydrogel formulation development, device engineering, veterinary treatment programs, and regulatory submissions. The RadioGel platform combines a radioactive isotope, typically yttrium-90 (Y-90), with a polymer-based hydrogel that can be injected directly into tumors. The company has indicated that this approach is intended to provide sustained localized radiation while minimizing migration from the treatment site.

Operations are primarily based in the United States, where the company conducts development, clinical preparation, and corporate activities. Vivos has collaborated with universities, veterinary oncology specialists, isotope suppliers, and contract research organizations to support technical development and treatment evaluations. Publicly available filings identify strategic relationships involving isotope handling and manufacturing support, though some partnership details remain limited in scope. The company does not currently report large-scale commercial revenue operations and remains largely in the development-stage medical technology category based on available SEC disclosures.

Strategic Position & Investments

Vivos’ strategic direction has centered on advancing the regulatory pathway and commercialization potential of the RadioGel platform in both veterinary and human oncology markets. The company has pursued growth through continued investment in isotope-based therapeutic technologies, intellectual property development, and regulatory engagement with U.S. authorities including the FDA and NRC. Public filings and company communications indicate that management views veterinary oncology applications as an operational proving ground that may support broader future oncology applications in humans.

The company’s investments have primarily focused on product development, radiation safety systems, manufacturing readiness, and clinical validation initiatives rather than diversified acquisitions. Vivos has emphasized the potential application of localized beta-emitting isotope therapies across multiple solid tumor indications. Available disclosures do not indicate a broad portfolio of subsidiaries or major acquired businesses comparable to larger biotechnology firms. Data regarding material international equity investments or extensive portfolio company ownership is inconclusive based on available public sources.

Geographic Footprint

Vivos’ operations are concentrated primarily in the United States, where its headquarters, development activities, and regulatory efforts are based. The company’s clinical and veterinary treatment initiatives have been conducted principally through U.S.-based collaborations and treatment centers. SEC filings and corporate disclosures do not indicate a large international operating infrastructure or multinational commercial footprint at this stage of development.

Although the company has discussed broader oncology market opportunities, publicly verified information indicates that its operational presence outside North America remains limited. International exposure currently appears tied more to the global applicability of isotope-based cancer therapies and supply-chain relationships than to direct overseas commercial operations. Data regarding material foreign subsidiaries or large-scale international facilities is inconclusive based on available public sources.

Leadership & Governance

Vivos Inc. is led by executives and directors with backgrounds in medical technology, engineering, radiation applications, and corporate development. Leadership communications have consistently emphasized advancing minimally invasive cancer therapies, regulatory progression, and long-term commercialization of localized radiotherapy technologies. Governance oversight is conducted through the company’s board structure as outlined in its SEC filings and annual reports.

Key executives and leadership figures include:

• Scott R. Schara – Chief Executive Officer
• Rusty DeGrezia – Chief Technology Officer
• Michael Korenko – Chairman of the Board

Public filings indicate that management’s strategic vision is focused on establishing the RadioGel platform as a differentiated localized cancer treatment technology with applications in veterinary and human oncology. Leadership has also emphasized regulatory compliance, intellectual property protection, and development-stage capital efficiency in shareholder communications and corporate presentations.